JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.13, sa.2, ss.204-207, 2017 (SCI-Expanded)
Backgrounds: The serum leptin level (SLL) has been shown to increase in patients with nonsmall cell lung cancer (NSCLC). However, available data regarding the relation between SLL and tumor subtypes, survival, cachexia, and tumor respectability in NSCLC are still under debate. The aim of this study is to evaluate SLL in NSCLC patients with and without cachexia.